Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2359${count})

  • Research Grant, 2023
    Measuring Quality of Life in People with Parkinson’s Disease: State of the Art and Areas for Development

    Study Rationale: Scales to measure quality of life are important tools for research. However, it is unclear whether currently available scales for measuring quality of life take into account the...

  • Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023
    Validation of KLK6 as a New Therapeutic Target for Parkinson’s Disease

    Study Rationale: Alpha-synuclein is the main protein that aggregates and forms Lewy bodies, the hallmark histological characteristics of Parkinson disease (PD). Multiple experimental studies suggest...

  • Novel PET Tracer Development Program, 2023
    Monitoring Glucocerebrosidase Engagement in Parkinson’s Disease

    Study Rationale: Glucocerebrosidase is an enzyme that is essential for maintaining healthy lipid metabolism throughout the human body. In Parkinson’s disease (PD), the efficiency of this protein is...

  • Research Grant, 2023
    Enhancing Access to Meaningful Data: Nebraska Parkinson’s Disease Registry

    Study Rationale: Nebraska’s Parkinson’s Disease Registry (NPDR) will roll out a new electronic data collection system, enforce state statutes requiring that physicians participate in reporting...

  • Research Grant, 2023
    Exploiting a Novel Mechanism for Gene Regulation to Develop Innovative, Targeted Therapies for Parkinson’s Disease

    Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are associated with a variety of disease-causing mutations and genetic variants. In addition...

  • Accelerating the Translation of Parkinson's Disease Therapies, 2023
    Development of Small Molecule Activators of Nurr1 as Potential Therapeutics for Parkinson's Disease

    Study Rationale: Parkonson’s disease (PD) is characterized by neuroinflammation and the death of dopamine-producing neurons. Nurr1 is a protein that regulates the activity of genes to reduce...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.